AUTHOR INDEX

Volume 59 • 1992

Abe, K., Takayanagi, M. and Saito, H.
EGF's trophic effect and protein kinase 259
Abe, M. *See* Oh-ishi, S.
Ahn, H.Y., Kang, S.E., Chang, K.C. and Karaki, H.
cAMP inhibits smooth muscle PI turnover 263
Aisaka, K., Miyazaki, T., Hidaka, T., Ohno, T., Ishihara, T. and Kanai, T.
Effect of carperitide and NO on hematocrit 489
Aishita, H. *See* Wakitani, K.
Akima, M. *See* Takanashi, H.
Akiyama, M. *See* Nakata, Y.
Akizawa, T. *See* Nakata, Y.
Ando, K. *See* Hironaka, N.
Aonuma, S. *See* Miyazawa, K.
Araki, H. *See* Shimada, C.
Araki, Y. *See* Shimizu, H.

Castellucci, A. *See* Evangelista, S.
Chang, K.C. *See* Ahn, H.Y.
Chiba, S. *See* Takei, M.
Chiba, S. and Tsukada, M.
Nonpeptide vasopressin V_1 & V_2 antagonists 133

Dabasaki, T., Shimojo, M., Ishikawa, H. and Uemura, A.
Anti-hypotensive effects of M6434 145

Ebihara, A. *See* Fujimura, A.
Ebii, K. *See* Taniguchi, T.
Evangelista, S., Maggi, C.A. and Castellucci, A.
Endothelins and kidney 239

Fujikawa, Y. *See* Yamamoto, T.
Fujimura, A., Ohira, H., Ohashi, K. and Ebihara, A.
Chronopharmacology of probucol 121
Fujimura, A., Sudoh, T., Shiga, T., Ohashi, K. and Ebihara, A.
Chronopharmacology of furosemide 209
Fujitani, B. *See* Wakitani, K.
Fujiwara, M. *See* Kitagawa, S.
—— *See* Taniguchi, T.
Fukami, M. *See* Kuroda, M.
Fukui, H., Yamamoto, Masaki and Sato, S.
Cisplatin-induced emesis in dogs 221
Fukunaga, R. *See* Taniguchi, T.
Fukushige, J. *See* Kuroda, M.
Fukutake, K. *See* Mizuguchi, K.
Furukawa, Y. *See* Takei, M.
Furuta, K. *See* Hattori, T.

Go, K. *See* Namimatsu, A.
Goh, C.R. *See* Tan, L.

Haga, K. *See* Sato, N.
Harada, M., Koike, K. and Takayanagi, I.
PrBCM-sensitive and -resistant receptors 485
Hasegawa, M. *See* Shimada, C.
Hashimoto, S., Oshita, M., Morikawa, K., Kato, Hideo, Ito, Y., Kigoshi, S. and Muramatsu, I.
HSR-175, a new α_1-adrenoceptor 379
Hata, T. *See* Namimatsu, A.
Hattori, T., Furuta, K., Nagao, T., Nagamatsu, T., Ito, M. and Suzuki, Y.
Antinephritic effect of berberine 159
Hattori, T., Hayashi, K., Nagao, T., Furuta, K., Ito, M. and Suzuki, Y.
Antinephritic effect of pachyman 89
Hayashi, K. *See* Hattori, T.
Hidaka, T. *See* Aisaka, K.
Hirai, Y. *See* Nakata, Y.
Hironaka, N., Miyata, H. and Ando, K.
Drug effects on memory in animals 113
Hirose, A. *See* Shimizu, H.
Hirouchi, M., Mizutani, H., Kohno, Y. and Kuriyama, K.
Brotizolam and benzodiazepine receptor 387
Horiba, M. *See* Watanabe-Kohno, S.
Hyun, S.-H. *See* Kim, D.-H.

Igata, H. *See* Okabe, S.
Ikeda, H. *See* Odaka, H.
Imai, S. *See* Kawada, T.
Imaizumi, N. *See* Kitagawa, S.
Inagaki, N. *See* Miura, T.
Inagaki, N., Miura, T., Nagai, H. and Koda, A.
ACA in the mouse ear 201
Inoue, K. *See* Watanabe-Kohno, S.
Inukai, T. *See* Noguchi, S.
Isaka, K. *See* Shimada, C.
Ishibashi, M. *See* Mizuguchi, K.
Ishihara, A., Saito, H. and Nishiyama, N.
bFGF and learning in BF-lesioned mice 7
Ishihara, T. *See* Aisaka, K.
Ishii, A. *See* Miki, I.
Ishikawa, H. *See* Dabasaki, T.
Itakura, H. *See* Kuroda, M.
Ito, K. *See* Iwamoto, T.
Ito, M. *See* Hattori, T.
Ito, M., Shii, D., Segami, T., Kojima, R. and Suzuki, Y.
Z-103 and free radical scavenging enzymes 267
Ito, T. *See* Kuroda, M.
Ito, Y. *See* Hashimoto, S.
Iwamoto, T., Morita, T., Sukamoto, T. and Ito, K.
KB-2796 and urine formation 137
Izawa, T. *See* Komabayashi, T.

Kageyama, M., Yamada, H., Satoh, K. and Taira, N.
Effects of semotiadil on AV conductivity 177
Kajimoto, N. *See* Nishimura, Y.
—— *See* Omote, M.
Kanai, T. *See* Aisaka, K.
Kaneto, H. *See* Takahashi, Masakatsu
—— *See* Tokuyama, S.
Kang, S.E. *See* Ahn, H.Y.
Karaki, H. *See* Ahn, H.Y.
Karasawa, A. *See* Shirakura, S.
Karasawa, Y. *See* Takei, M.
Kataoka, Y., Niwa, M., Koizumi, S., Watanabe, S., Kouzuma, M. and Taniyama, K.

Nebracetam and NMDA-induced neurotoxicity 247
Kato, Hideo *See* Hashimoto, S.
Kato, Hitoshi *See* Kurihara, J.
Kato, S. *See* Okabe, S.
Kato, T. *See* Sakamoto, O.
Kawada, T., Yoshida, Y., Sakurai, H. and Imai, S.
Na^+ and Ca^{2+} in ischemia-reperfusion 191
Kawasaki, H., Nakamura, S. and Takasaki, K.
Central pressor by clonidine in SHR 321
Kigoshi, S. *See* Hashimoto, S.
—— *See* Muramatsu, I.
—— *See* Nishio, M.
Kim, D.-H., Hyun, S.-H., Shim, S.-B. and Kobashi, K.
Bacterial transformation of picosulfate 1
Kim, H.-S. *See* Tokuyama, S.
Kimura, I., Naitoh, T., Okabe, M. and Kimura, M.
PDGF accelerates competence-induction 51
Kimura, M. *See* Kimura, I.
Kishibayashi, N. *See* Miki, I.
Kita, T. *See* Okamoto, M.
Kitagawa, S., Yamaguchi, Y., Kunitomo, M., Imaizumi, N. and Fujiwara, M.
Impairment of EDR in arteriosclerosis 339
Kitaichi, K. *See* Sakamoto, O.
Kobashi, K. *See* Kim, D.-H.
Koda, A. *See* Inagaki, N.
—— *See* Miura, T.
—— *See* Sakamoto, O.
Kohno, Y. *See* Hirouchi, M.
Koike, K. *See* Harada, M.
Koizumi, S. *See* Kataoka, Y.
Kojima, M. *See* Mizuguchi, K.
Kojima, R. *See* Ito, M.
Kokubu, N. *See* Takayanagi, I.
Komabayashi, T., Yakata, A., Izawa, T., Noguchi, M., Suda, K. and Tsuboi, M.
Diacylglycerol formation and PC hydrolysis 97
Kouzuma, M. *See* Kataoka, Y.
Kubo, K. *See* Shirakura, S.
Kubota, K. *See* Sugaya, K.
Kunitomo, M. *See* Kitagawa, S.
Kuribara, H. and Tadokoro, S.
Ethanol intoxication and caffeine 393
Kurihara, J., Sahara, T., Tamaoki, S. and Kato, Hitoshi
MK-801 and cerebral ischemia in dogs 243
Kuriyama, K. *See* Hirouchi, M.
Kuroda, M., Matsumoto, A., Itakura, H., Watanabe, Y., Ito, T., Shiomi, M., Fukushige, J., Nara, F., Fukami, M. and Tsujita, Y.
LDL receptor induction in WHHL rabbit 65
Kuroda, S. *See* Shimada, C.
Kuroyanagi, N. *See* Nakata, Y.

Lin, M.-T. *See* Won, S.-J.

Maggi, C.A. *See* Evangelista, S.
Masada, A. *See* Mizuguchi, K.
Matsuda, S., Saito, H. and Nishiyama, N.
Effect of bFGF on transplantation 365
Matsumoto, A. *See* Kuroda, M.
Matsumoto, J. *See* Takeuchi, K.
Mikami, T. *See* Miyazawa, K.
Miki, I., Kishibayashi, N., Nonaka, H., Ohshima, E., Takami, H., Obase, H. and Ishii, A.
KW-3635, a new TXA_2 receptor antagonist 357
Miki, N. *See* Odaka, H.
Mita, S. *See* Sasano, M.
Mitsui, Y. *See* Okamura, N.
Miura, T., Inagaki, N., Yoshida, K., Nakajima, T., Nagai, H. and Koda, A.
Anti-allergic action of glucocorticoids 77
Miura, T. *See* Inagaki, N.
Miyasaka, K. *See* Miyazawa, K.
Miyata, H. *See* Hironaka, N.
Miyazaki, T. *See* Aisaka, K.
Miyazawa, K., Mikami, T., Miyasaka, K. and Aonuma, S.
Acute and chronic sialoadenitis 405
Mizota, M. *See* Mizuguchi, K.
Mizuguchi, K., Yano, T., Kojima, M., Tanaka, Y., Ishibashi, M., Masada, A., Sato, M., Mizota, M., Fukutake, K. and Saito, Y.
Hypolipidemic action of EPA-E 307
Mizusawa, H. *See* Omote, M.
Mizutani, H. *See* Hirouchi, M.
Mori, H. *See* Sakamoto, O.
Morikawa, K. *See* Hashimoto, S.
Morita, T. *See* Iwamoto, T.
Murakami, M. *See* Takei, M.
Muramatsu, I. and Kigoshi, S.
Tizanidine and imidazoline-receptor 457
Muramatsu, I. *See* Hashimoto, S.
—— *See* Nishio, M.
Murayama, S. *See* Okamoto, Y.

Nagai, H. *See* Inagaki, N.
—— *See* Miura, T.
Nagamatsu, T. *See* Hattori, T.
Nagano, Nobuo, Yagi, M. and Nishikori, K.
Role of reactive oxygen species in acute renal failure 481
Nagano, Noriko *See* Odaka, H.
Nagao, T. *See* Hattori, T.
Nagaoka, A. *See* Odaka, H.
Naitoh, T. *See* Kimura, I.
Nakaji, S. *See* Okabe, S.
Nakajima, T. *See* Miura, T.
Nakamura, M. *See* Shimizu, H.
Nakamura, S. *See* Kawasaki, H.
Nakashima, T. *See* Okamoto, M.
Nakata, K. *See* Sasano, M.
Nakata, Y., Takamatsu, H., Kuroyanagi, N., Nishio, H., Segawa, T., Akizawa, T., Hirai, Y. and Akiyama, M.
Substance P binding protein 313
Namimatsu, A., Go, K. and Hata, T.
Nasal hypersensitivity and neurotropin 371
Namimatsu, A., Okazaki, R., Go, K. and Hata, T.
Nasal hypersecretion and muscarinic receptors 427
Nara, F. *See* Kuroda, M.
Narita, M. *See* Takei, M.
Ninomiya, H. *See* Taniguchi, T.
Nishikori, K. *See* Nagano, Nobuo
Nishimura, Y., Usui, H., Suzuki, A., Kajimoto, N. and Yamanishi, Y.
Response of SHRSP basilar arteries to CGRP 333
Nishio, H. *See* Nakata, Y.
Nishio, M., Muramatsu, I. and Kigoshi, S.
Pentazocine and lymphocyte cytotoxicity 71
Nishiyama, N. *See* Ishihara, A.

—— *See* Matsuda, S.
Niwa, M. *See* Kataoka, Y.
Noguchi, M. *See* Komabayashi, T.
Noguchi, S. and Inukai, T.
Histamine H_1 receptors and PI response 31
Nomura, Y. *See* Tohda, M.
Nonaka, H. *See* Miki, I.

Obase, H. *See* Miki, I.
Odaka, H., Nagano, Noriko, Miki, N., Ikeda, H. and Nagaoka, A.
Effect of manidipine on SMC proliferation 255
Ogihara, M.
Nifedipine and hepatic gluconeogenesis 413
Oh, K.-W. *See* Tokuyama, S.
Oh-ishi, S., Yamaki, K., Abe, M., Tomoda, H. and Ōmura, S.
Triacsin enhances arachidonate release 417
Ohashi, K. *See* Fujimura, A.
Ohata, K. *See* Watanabe-Kohno, S.
Ohira, H. *See* Fujimura, A.
Ohkawa, E. *See* Watanabe-Kohno, S.
Ohno, M. *See* Yamamoto, T.
Ohno, T. *See* Aisaka, K.
Ohshima, E. *See* Miki, I.
Okabe, M. *See* Kimura, I.
Okabe, S. *See* Takeuchi, K.
Okabe, S., Nakaji, S. and Tachibana, M.
Ketotifen and gastric lesions 251
Okabe, S., Takagi, K., Igata, H., Kato, S., Shimosako, K., Yamaji, Y. and Seiki, M.
A new H_2-antagonist, Z-300 275
Okamoto, M., Kita, T., Okuda, H. and Nakashima, T.
Nicotine-induced convulsions 449
Okamoto, Y., Suzuki, T. and Murayama, S.
Opioid antagonists in spinal ischemia 435
Okamura, N., Shirasawa, Y. and Mitsui, Y.
Dilazep on cytosolic Ca^{2+} in endotherial cells 183
Okazaki, R. *See* Namimatsu, A.
Okuda, H. *See* Okamoto, M.
Omote, M., Kajimoto, N. and Mizusawa, H.
Phenylephrine-induced rhythmic behavior 37
Ōmura, S. *See* Oh-ishi, S.
Oshita, M. *See* Hashimoto, S.

Porter, A.G. *See* Tan, L.

Ren, L.-M. *See* Takei, M.

Sahara, T. *See* Kurihara, J.
Saito, H. *See* Abe, K.
—— *See* Ishihara, A.
—— *See* Matsuda, S.
Saito, Y. *See* Mizuguchi, K.
Sakamori, M. *See* Sato, N.
Sakamoto, O., Mori, H., Kitaichi, K., Koda, A. and Kato, T.
Low immunosuppressive fluoropyrimidines 469
Sakurai, H. *See* Kawada, T.
Sano, J. *See* Shirakura, S.
Sano, M. *See* Shimada, C.
Sasano, M., Nakata, K. and Mita, S.
Inhibition of TNF production by SA3443 493
Sato, M. *See* Mizuguchi, K.
Sato, N., Sakamori, M., Haga, K., Takehara, S. and Setoguchi, M.
Antagonism of 5-HT_3 receptor by Y-25130 443
Sato, S. *See* Fukui, H.
Satoh, K. *See* Kageyama, M.
Segami, T. *See* Ito, M.
Segawa, T. *See* Nakata, Y.
Seiki, M. *See* Okabe, S.
Setoguchi, M. *See* Sato, N.
Shiga, T. *See* Fujimura, A.
Shii, D. *See* Ito, M.
Shikada, K. *See* Yamamoto, A.
Shim, S.-B. *See* Kim, D.-H.
Shimada, C., Tanaka, Schuichi, Hasegawa, M., Kuroda, S., Isaka, K., Sano, M. and Araki, H.
Taurine infusion in GES-treated rats 43
Shimizu, H., Tatsuno, T., Tanaka, H., Hirose, A., Araki, Y. and Nakamura, M.
Pharmacological mechanism of tandospirone 105
Shimojo, M. *See* Dabasaki, T.
Shimosako, K. *See* Okabe, S.
Shiomi, M. *See* Kuroda, M.
Shiraishi, K. *See* Takayanagi, I.
Shirakura, S., Sano, J., Karasawa, A. and Kubo, K.
Cerebral infarction and benidipine 15
Nephrotic syndrome and benidipine 461
Shirasawa, Y. *See* Okamura, N.
Suda, K. *See* Komabayashi, T.
Sudoh, T. *See* Fujimura, A.
Sugaya, K., Takahashi, Masanori and Kubota, K.
CCK preserves cholinergic neurons 125
Sugioka, M. *See* Wakitani, K.
Sukamoto, T. *See* Iwamoto, T.
Suzuki, A. *See* Nishimura, Y.
Suzuki, T. *See* Okamoto, Y.
Suzuki, Y. *See* Hattori, T.
—— *See* Ito, M.

Tachibana, K. *See* Takeuchi, K.
Tachibana, M. *See* Okabe, S.
Tadokoro, S. *See* Kuribara, H.
Taira, N. *See* Kageyama, M.
—— *See* Yamagishi, T.
Takagi, K. *See* Okabe, S.
Takahashi, Masakatsu *See* Tokuyama, S.
Takahashi, Masakatsu, Tokuyama, S. and Kaneto, H.
Ginseng vs stress in morphine tolerance 399
Takahashi, Masanori *See* Sugaya, K.
Takakuwa, T. *See* Wakitani, K.
Takamatsu, H. *See* Nakata, Y.
Takami, H. *See* Miki, I.
Takanashi, H. and Akima, M.
Gastric blood flow and arbaprostil 349
Takasaki, K. *See* Kawasaki, H.
Takayanagi, I., Shiraishi, K. and Kokubu, N.
α_{1B}-Adrenoceptors in rabbit iris dilator 301
Takayanagi, I. *See* Harada, M.
Takayanagi, M. *See* Abe, K.
Takehara, S. *See* Sato, N.
Takei, M., Furukawa, Y., Narita, M., Murakami, M., Ren, L.-M., Karasawa, Y. and Chiba, S.
β_2-Adrenoceptor of SA and AV nodes 23
Takeuchi, K., Tachibana, K., Ueshima, K., Matsumoto, J. and Okabe, S.

Capsaicin on HCO_3^- secretion 151
Tamaoki, S. *See* Kurihara, J.
Tan, L., Goh, C.R. and Porter, A.G.
Liposomal rhTNF-β cytotoxicity 235
Tanaka, H. *See* Shimizu, H.
Tanaka, Sakuya *See* Yamamoto, A.
Tanaka, Shuichi *See* Shimada, C.
Tanaka, Y. *See* Mizuguchi, K.
Taniguchi, T., Ninomiya, H., Fukunaga, R., Ebii, K., Yamamoto, Masato and Fujiwara, M.
PI turnover by NKA in iris muscle 213
Taniyama, K. *See* Kataoka, Y.
Tatsuno, T. *See* Shimizu, H.
Tohda, M., Urushihara, H. and Nomura, Y.
Tryptophan inhibits the glutamate uptake 477
Tokuyama, S. *See* Takahashi, Masakatsu
Tokuyama, S., Oh, K.-W., Kim, H.-S., Takahashi, Masakatsu and Kaneto, H.
Ginseng and reverse tolerance to MAP 423
Tomoda, H. *See* Oh-ishi, S.
Tsuboi, M. *See* Komabayashi, T.
Tsujita, Y. *See* Kuroda, M.
Tsukada, M. *See* Chiba, S.

Ueki, S. *See* Yamamoto, T.
Uemura, A. *See* Dabasaki, T.
Ueshima, K. *See* Takeuchi, K.
Urushihara, H. *See* Tohda, M.
Usui, H. *See* Nishimura, Y.

Wakitani, K., Takakuwa, T., Sugioka, M., Fujitani, B. and Aishita, H.
OP-41483 on peripheral vascular lesion 57
Watanabe, S. *See* Kataoka, Y.
Watanabe, Y. *See* Kuroda, M.
Watanabe-Kohno, S., Yasui, K., Ohkawa, E., Yamamura, H., Horiba, M., Inoue, K. and Ohata, K.
Antiallergic effect of AS-35 227
Won, S.-J., Lin, M.-T. and Wu, W.-L.
Ganoderma tsugae enhances NK activity and IFN production 171
Wu, W.-L. *See* Won, S.-J.

Yagi, M. *See* Nagano, Nobuo
Yakata, A. *See* Komabayashi, T.
Yamada, H. *See* Kageyama, M.
Yamagishi, T., Yanagisawa, T. and Taira, N.
Cromakalim & agonist's contraction 291
Yamaguchi, Y. *See* Kitagawa, S.
Yamaji, Y. *See* Okabe, S.
Yamaki, K. *See* Oh-ishi, S.
Yamamoto, A., Shikada, K. and Tanaka, Sakuya
Anti-asthma drugs and tracheal nerves 129
Yamamoto, Masaki *See* Fukui, H.
Yamamoto, Masato *See* Taniguchi, T.
Yamamoto, T., Ohno, M., Yatsugi, S., Fujikawa, Y. and Ueki, S.
Head-twitches and nootropics 419
Yamamura, H. *See* Watanabe-Kohno, S.
Yamanishi, Y. *See* Nishimura, Y.
Yanagisawa, T. *See* Yamagishi, T.
Yano, T. *See* Mizuguchi, K.
Yasui, K. *See* Watanabe-Kohno, S.
Yatsugi, S. *See* Yamamoto, T.
Yoshida, K. *See* Miura, T.
Yoshida, Y. *See* Kawada, T.

SUBJECT INDEX

Volume 59 • 1992

A23187 97
Acetylcholine 419
Active cutaneous anaphylaxis 201
Acyl-CoA synthetase 417
Administration-time-dependent 209
Adrenal corticoid 209
α_1-Adrenoceptor 301, 379
α_2-Adrenoceptor 457
α_1-Adrenoceptor antagonist 379
β-Adrenoceptor 23
Affinity chromatography (substance P) 313
α_1-Agonist 145
Allergic rhinitis 427
Alzheimer's disease 125
Anaphylaxis 227
Anti-allergic action 77
Anti-allergic drug 201, 371
Anti-asthma drug 129
Anti-GBM nephritis 89
Anti-stress effect 399
Anticonflict action 105
Antidepressant 31
Antimyoproliferative action 255
Antiplatelet activity 57
Anxiolytics 105
Apomorphine 365
Arachidonic acid 15, 417
Arbaprostil 349
Arteriosclerosis 339
AS-35 (9-[(4-acetyl-3-hydroxy-2-*n*-propyl-phenoxy)methyl]-3-(1*H*-tetrazol-5-yl)-4*H*-pyrido[1,2-*a*]pyrimidin-4-one) 227
Atenolol 23
Atrial natriuretic peptide 489
Atrioventricular conduction 177

Baroreflex 243
Basal forebrain lesion 7, 125
Basic fibroblast growth factor (bFGF) 7, 365
Basilar artery 333
Behavior disruption 393
Benidipine 15, 461
Benzodiazepine receptor 387
Berberine 159
Binding protein 313
Biotransformation 1
Blood pressure 177
Blood vessel 379
Bowman's capsule 89
Brain (rat) 313
Brain mRNA 477
Brain nicotine level 449
Bronchus (human) 227
Brotizolam 387

C3 deposition 89
C3H/HeN mouse 171
Ca^{2+} accumulation 191
Ca^{2+} channel 291
Ca^{2+} spiking 183
Caffeine 393
Calcification 339
Calcitonin gene-related peptide (CGRP) 333
Calcium antagonist 137, 177
Capsaicin 151
Capsaicin-sensitive afferents 151
Cell proliferation 51
Cell transplantation 365
Central pressor response 321
Central type I benzodiazepine receptor 387
Central α_2-adrenoceptor 321
Cerebellum 387
Cerebral cortex (rat) 31
Cerebral edema 15
Cerebral ischemia (acute) 15, 243
Cholecystokinin 125
Cholesterol 121
Cholestyramine 65
Choline acetyltransferase activity 7
Chronopharmacology 121
Cisplatin-induced emesis 221
Clofibrate 307
Clonidine 301, 321
Cobaltic EDTA 191
Convulsion 449
Coptidis rhizoma 159
Coptisine 159
Cortisone-resistant lymphocytes 71
Cromakalim 291
Cyclic AMP 263
Cycloheximide 77
Cytoprotection 251
Cytosolic Ca^{2+} 183
Cytotoxicity 71

Delayed discrimination 113
Delayed matching to sample 113
Deoxycorticosterone acetate (DOCA)hypertension 209
sn-1,2-Diacylglycerol accumulation 97
5,7-Dihydroxytryptamine 105
Dilazep 183
Discrete avoidance (mouse) 393
Diurnal variation 209
Duodenum 151

Ear (mouse) 201
Ehrlich carcinoma cell 71
Electroretinogram 43
Endothelial cell 183
Endothelin 239
Endothelium 37, 333
Endothelium-dependent relaxation 339
Endothelium-derived relaxing factor (EDRF) 37
EPA-E (ehtyl *all-cis*-5,8,11,14,17-icosapentaenoate) 307
Epidermal growth factor 259
Ethanol 267, 393
Extracellular calcium ion 37

5-Fluorouracil 469
5-Fluorouridine 469
Furosemide 209

Ganoderma tsugae mycelium 171
Gastric blood flow 349
Gastric lesion 251, 267, 349
Gastric secretion 275
Gastro-duodenal lesion 275
Ginseng extract 399, 423
Glucocorticoid 77
Gluconeogenesis 413
Glutamate uptake 477
Glutathione peroxidase 267
Guanidinoethyl sulfonate 43

HCO_3^- secretion 151
Head-twitch 419
Heart (isolated) 443
Heart rate 23
Hematocrit 489
Heparin 51
High-cholesterol diet 339
Histamine 183
Histamine H_1 receptor 31
Histamine H_2-receptor antagonist 275
HSR-175 (*R*-(−)-5-[2-[[2-(5-fluoro-2-methoxyphenoxy)ethyl]amino]propyl]-2-methoxybenzensulphonamide hydrochloride) 379
5-HT_{1A} receptor 105
5-HT_3 receptor 443
5-HT_3 receptor antagonist 221
3-Hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor 65
Hypolipidemic action 307

ICI 118,551 (erythro[±]-1-[7-methylindan-4-yloxy]-3-isopropyl-aminobutan-2-ol) 23
IgE antibody 201
IgG1 antibody 201
Ileum (isolated) 443
Imidazoline-receptor 457
Indomethacin 349
Inflammation 405
Interferon production (serum) 171
Intestinal flora 1
Intoxication 393
Intracellular calcium concentration 291
Intracellular cation contents 191
Iris dilator (rabbit) 301
Iris sphincter muslce (rabbit) 213

K^+ channel 291

KB-2796 (1-[bis(4-fluorophenyl)methyl]-4-(2,3,4-trimethoxybenzyl)piperazine dihydrochloride) 137
Ketotifen 251
Kidney (isolated and perfused) 239
Kidney (rat) 457
KW-3635 (sodium (*E*)-11-[2-(5,6-dimethyl-1-benzimidazolyl)ethylidene]-6,11-dihydrodibenz[*b*,*e*]oxepin-2-carboxylate monohydrate) 357

L929 cell 235
Laxative 1
Leukocyte 405
Leukotriene D_4 (LTD_4) 227
Levallorphan 435
Levoprotiline 31
Liposomes 235
Low density lipoprotein (LDL) receptor 65
Lung (human) 227

M6434 (2-[(5-chloro-2-methoxyphenyl)azo]-1*H*-imidazole) 145
Manidipine 255
Memory deficit 7
Mesenteric artery (rabbit) 37
Methamphetamine 423
Methoxamine 301
Midodrine 145
MK-801 (5-methyl-10,11-dihydro-5*H*-dibenzo[*a*,*d*]cyclohepten-5,10-imine) 243
Monensin 191
Morphine tolerance 399
Muscarinic m3 subtype 485
Muscarinic receptor 427
Myeloperoxidase activity 405

Na^+-Ca^{2+} exchange 191
Naloxone 435
Nasal allergy 371
Nasal hypersensitivity 371, 427
Nasal provocation 427
Natural killer (splenic) 171
Nebracetam 247
Neo-intima 255
Nephritis 159
Nephrotic syndrome 461
Neurally-mediated contraction 129
Neurokinin A-induced contractile response 213
Neurokinin A-stimulated PI turnover 213
Neuroprotective action 247
Neurotrophic effect 259
Neurotropin 371
Nicardipine 15
Nicotine 449
Nifedipine 413
Nitric oxide 489
Nonradioactive microsphere 349
Nootropics 419
Normotensive Wistar Kyoto rat 321

OP-41483·α-CD (5(*E*)-6,9α-methylene-15-cyclopentyl-16,17,18,19,20-pentanor-PGI_2-α-cyclodextrin clathrate 57
Open-chest dog (anesthetized) 177
Orthostatic index 145

Pachyman 89
Paraquat 481
Parotid acinar cell 97
Parotid gland 405
Passive cutaneous anaphylaxis 77
Pentazocine 71
Peripheral vascular lesion 57
Pharmacokinetics 121
Phenylephrine-induced oscillation 37
Phorbol 12,13-dibutyrate 97
Phosphatidylcholine hydrolysis 97
Phosphatidylinositol turnover 263
Phosphoinositide hydrolysis (PI) response 31
Picosulfate 1
Plasma renin activity 137
Platelet-derived growth factor 51
Platelet 357
Polyclonal antibody (substance P) 313
Polysynaptic reflex 435
Postural hypotension 145
Pravastatin 65
Primary cultures of rat hepatocytes 413
Probucol 121
Propylbenzilylcholine mustard (PrBCM) receptor 485
Prostacyclin analog 57
Prostaglandin E_1 57
Protein kinase inhibitor 259
Protein synthesis 77
Proteinuria 159
Psychoactive drug 113
Puromycin aminonucleoside 461

Reactive oxygen species 481
Renal failure (acute) 481
Renal hemodynamics 137
Retina 43
Reverse tolerance 423
Rotational behavior 365

SA3443 ((4*R*)-hexahydro-7,7-dimethyl-6-oxo-1,2,5-dithiazocine-4-carboxylic acid) 493
Semotiadil (SD-3211, (+)-(*R*)-2-[5-methoxy-2-[3-[methyl-[2-[3,4-(methylenedioxy)-phenoxy]ethyl]amino]propoxy]phenyl]-4-methyl-2*H*-1,4-benzothiazine-3(4*H*)-one hydrogen fumarate) 177
Serum antibody level 427
Serum complement CH_{50} 89
Short-term memory 113
Sialoadenitis 405
Spinal cord 387
Spinal cord ischemia 435
Spinal interneuron 435
Spontaneously hypertensive rat 239, 321
Step-through test 7
Stomach 151
Stress 371
Stress-induced analgesia (SIA) 399
Striatal slices (rat) 247
Stroke-prone spontaneously hypertensive rats (SHRSP) 333
Substance P 313
Substance P antagonists 213
[^{3}H]-Substance P binding 213
α_{1B}-Subtype 301
Sulfotransferase 1
Superoxide dismutase 267
Sympathetic nerve stimulation 23

Tandospirone (3aα,4β,7β,7aα-hexahydro-2-(4-(4-(2-pyrimidinyl)-1-piperazinyl)-butyl)-4,7-methano-1*H*-isoindole-1,3-(2*H*)dione dihydrogen citrate) 105
Taurine 43
Taurine deficient rat 43
Thromboxane A_2 analogue 291
Thromboxane A_2 antagonist 357
Thromboxane A_2/prostaglandin H_2 receptors 357
Thymus 71
Tizanidine 457
Tolerance 449
Tolerance to stress-induced analgesia (SIA) 399
Trachea (guinea pig) 129
Tremor 449
Triacsin C 417
Tumor necrosis factor (TNF) 493
Tumor necrosis factor-β 235

UK-21 (2',3',5'-tris-*O*-[*N*-(2-*n*-propyl-*n*-pentanoyl)glycyl]-5-fluorouridine) 469
UK-25 (1-|6-[*N*-(2-*n*-propyl-*n*-pentanoyl)-glycyl]amino-*n*-hexylcarbamoyl|-5-fluorouracil) 469
Ulcer healing 275
Urine formation 137

V_1-antagonist 133
V_2-antagonist 133
Vagal afferent 221
Vascular relaxation 333
Vascular smooth muscle 51
Vasodilation 263
Vasopressin receptor subtype 133
Vitamin D 339

Watanabe heritable hyperlipidemic (WHHL) rabbit 65

Xenopus oocytes 477

Y-25130 ((±)-*N*-(1-azabicyclo[2.2.2]oct-3-yl)-6-chloro-4-methyl-3-oxo-3,4-dihydro-2*H*-1,4-benzoxazine-8-carboxamide monohydrochloride) 443

Z-103 (*N*-(3-aminopropionyl)-L-histidinato zinc) 267
Z-300 (*N*-[3-[3-(piperidinomethyl)phenoxy]-propyl]-2-(2-hydroxyethyl-1-thio)-acetamido·2-(4-hydroxy benzoyl)benzoate) 275